Clavis Pharma

Industry · 11 registered clinical trials.

Status	Trial	Phase	Started
Completed	Elacytarabine Mass Balance Study in Healthy Volunteers Not Applicable as This is a Mass Balance/Pharmacokinetic Study Performed in Healthy Subjects	Phase 1	2013-02-01
Completed	The Pharmacokinetics and Cardiac Properties of Elacytarabine (CP-4055) Relapsed/Refractory AML	Phase 1	2010-10-01
Completed	Study of Elacytarabine Versus Investigator's Choice in Patients With Late Stage Acute Myeloid Leukaemia (AML) Acute Myeloid Leukemia (AML)	Phase 3	2010-06-01
Completed	A Study of Elacytarabine (CP-4055) Plus Idarubicin as Second Course Remission-Induction Therapy in Patients Wi Acute Myeloid Leukemia	Phase 2	2009-12-01
Completed	A Study of CP-4126 in Patients With Advanced Pancreatic Cancer Advanced Adenocarcinoma of Pancreas	Phase 2	2009-04-01
Completed	A Phase I Clinical Study of Oral CP-4126 in Patients With Advanced Solid Tumour Solid Tumors	Phase 1	2008-10-01
Completed	A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer Ovarian Cancer	Phase 1 / Phase 2	2008-04-01
Completed	A Phase II Study of CP-4055 as Second Line Therapy in Patients With Advanced Colorectal Cancer Advanced Colorectal Cancer, Colorectal Cancer	Phase 2	2007-05-01
Completed	Multicentre, Dose Finding, Ph II,CP-4055 in Comb. With Sorafenib - Patients With Metastatic Malignant Melanoma Malignant Melanoma	Phase 2	2007-03-01
Completed	A Phase I/II Study of CP-4055 in Patients With Refractory/Relapsed Hematologic Malignancies Hematologic Malignancies, AML	Phase 1 / Phase 2	2006-05-01
Completed	Clinical Study of Previously Untreated Patients With Malignant Melanoma Malignant Melanoma, Neoplasm Metastasis	Phase 2	2005-09-01